Objective: A young age at diagnosis of breast cancer as a negative prognostic factor is a controversial issue. Some reports indicate that breast cancer in young women has different clinicopathological characteristics than in the elderly, while others found no correlation between prognosis and age. The aim of the present study was to assess the clinicopathological characteristics and prognostic factors of breast cancer in young women compared with elderly patients.
Material And Methods: Thirty-seven operable breast cancer patients below 40 years of age, treated with mastectomy or breast conserving treatment and radiation therapy with or without adjuvant chemotherapy and tamoxifen, were assessed clinically and pathologically. Tumor size, lymph node status, histological grade, mitotic index, presence of estrogen and progesterone receptors, c-erbB2 expression, p53 and the MIB-1 proliferation index were evaluated histopathologically and immunohistochemically. Prognostic factors were compared to those for breast cancer patients age 60 years and older, with special attention to recurrence, distant metastasis and five-year survival between two groups.
Results: Breast cancer in young women showed a more aggressive phenotype than in elderly patients, with a larger tumor size, more lymph node involvement, and higher c-erbB2 and p53 expression, although the latter were usually limited to more advanced stages. A higher MIB-1 proliferation index than in the elderly group was also noted, despite higher positivity and ER and PR. While adjuvant chemotherapy, including tamoxifen treatment, was more common, recurrence, metastasis and death were still higher than in elderly patients.
Conclusion: Thus a young age is associated with a poor prognosis in Indonesia.
Download full-text PDF |
Source |
---|
Pathol Res Pract
December 2024
Department of Zoology (PG), Vellalar College for Women, Erode, India. Electronic address:
Breast cancer remains the leading cause of mortality among women with cancer. This article delves into the intricate relationship between breast cancer and cancer stem cells (CSCs), emphasizing advanced methods for their identification and isolation. The key isolation techniques, such as the mammosphere formation assay, surface marker identification, Side Population assay, and Aldehyde Dehydrogenase assay, are critically examined.
View Article and Find Full Text PDFTransl Oncol
January 2025
Department of Surgery, The Second Affiliated Hospital of Jiaxing University, No. 397, Huangcheng North Road, Jiaxing, Zhejiang, 314000, China. Electronic address:
Epidermal growth factor receptor (EGFR) plays an important role in the regulation of cell proliferation and migration [1]. It forms a homodimer or heterodimer with other ErbB receptor family members to activate downstream signaling. Emerging evidence indicates that the EGFR activity and downstream signaling are regulated by other proteins except its family members during tumorigenesis.
View Article and Find Full Text PDFJCO Clin Cancer Inform
January 2025
SimBioSys Inc, Chicago, IL.
Purpose: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers.
Methods: Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency.
Eur J Cancer Prev
September 2024
Department of Oncology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China and.
Background: We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of neoadjuvant chemotherapy in HER2-low breast cancer patients.
Methods: The study endpoint was pathological complete remission (PCR). Blood specimens and fresh cancer tissue samples were collected before neoadjuvant chemotherapy for whole-exon sequencing (WES) and RNA sequencing (RNA-seq), and patients were divided into a human epidermal growth factor receptor 2 (HER2)-low group and a HER2-0 group according to their HER2 expression status via bioinformatics analysis.
Anticancer Drugs
January 2025
Department of Breast Surgery, the First People's Hospital of Lianyungang, The Affiliated Hospital of XuZhou Medical University, Lianyungang, Jiangsu Province, China.
This study aimed to evaluate the efficacy of pyrotinib, an orally administered small molecule tyrosine kinase inhibitor, combined with neoadjuvant chemotherapy in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Pyrotinib works by inhibiting the HER2 signaling pathway, thereby preventing tumor cell growth. This single-arm clinical trial aimed to assess the total pathological complete response (tpCR; ypT0/is and ypN0) rate as the primary endpoint.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!